Related Experiment Video
Updated: Apr 7, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Current Immunotherapies for Renal Cell Carcinoma
Mhd Yaser Al-Marrawi, Sheldon L Holder1
1Pennsylvania State Hershey Cancer Institute, Division of Hematology and Oncology, 500 University Drive, Mail code CH46, B.O. Box 850, Hershey, PA 17033. sholder@hmc.psu.edu.
Immunotherapy shows promise for renal cell carcinoma (RCC) treatment. New agents, including immune checkpoint inhibitors, are being investigated to improve patient outcomes and accessibility.
Area of Science:
- Oncology
- Immunology
Background:
- Immunotherapy is a rapidly evolving cancer treatment modality.
- Renal cell carcinoma (RCC) shows potential for favorable responses to immunotherapy, notably high-dose interleukin-2.
Purpose of the Study:
- To review current and emerging immunotherapeutic options for renal cell carcinoma.
- To examine approved therapies and agents in clinical trials for RCC.
Main Methods:
- Review of approved immunotherapies for RCC.
- Examination of novel immunotherapeutic agents in clinical trials.
- Analysis of different immunotherapy types: cytokine therapy, immune checkpoint blockade, hematopoietic stem cell transplant, and vaccine therapy.
Main Results:
- A subset of RCC patients achieve durable responses with high-dose interleukin-2.
- Multiple new immunotherapy targets and agents are under development for RCC.
- Various immunotherapeutic strategies are being investigated in clinical trials for RCC.
Conclusions:
- Immunotherapy remains a highly promising treatment modality for renal cell carcinoma.
- The development of novel agents aims to provide more accessible and effective treatment options for RCC patients and oncologists.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

